733 related articles for article (PubMed ID: 11182006)
1. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Research Committee of the British Thoracic Society
Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment.
Eur Respir J; 2003 Mar; 21(3):478-82. PubMed ID: 12662005
[TBL] [Abstract][Full Text] [Related]
3. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
Jenkins PA; Campbell IA; Banks J; Gelder CM; Prescott RJ; Smith AP
Thorax; 2008 Jul; 63(7):627-34. PubMed ID: 18250184
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment.
Jenkins PA; Campbell IA;
Respir Med; 2003 Apr; 97(4):439-44. PubMed ID: 12693807
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.
Int J Tuberc Lung Dis; 2002 Jul; 6(7):628-34. PubMed ID: 12102303
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
[TBL] [Abstract][Full Text] [Related]
7. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.
Banks J; Jenkins PA
Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264
[TBL] [Abstract][Full Text] [Related]
8. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis.
Al Jarad N; Demertzis P; Jones DJ; Barnes NC; Rudd RM; Gaya H; Wedzicha JA; Hughes DT; Empey DW
Thorax; 1996 Feb; 51(2):137-9. PubMed ID: 8711643
[TBL] [Abstract][Full Text] [Related]
9. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex.
Hunter AM; Campbell IA; Jenkins PA; Smith AP
Thorax; 1981 May; 36(5):326-9. PubMed ID: 7313999
[TBL] [Abstract][Full Text] [Related]
11. [Mycobacterium xenopi lung infection in a patient with multiple lung cysts that responded well to chemotherapy: a case report].
Gochi M; Kaneko Y; Seki A; Saitou Z; Samejima T; Seki Y; Takeda H; Kinoshita A; Kuwano K
Kekkaku; 2012 Nov; 87(11):733-6. PubMed ID: 23367833
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.
Miwa S; Shirai M; Toyoshima M; Shirai T; Yasuda K; Yokomura K; Yamada T; Masuda M; Inui N; Chida K; Suda T; Hayakawa H
Ann Am Thorac Soc; 2014 Jan; 11(1):23-9. PubMed ID: 24298907
[TBL] [Abstract][Full Text] [Related]
13. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
Heginbothom ML
Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581
[TBL] [Abstract][Full Text] [Related]
14. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
[TBL] [Abstract][Full Text] [Related]
16. [Study of the drug-sensitivity of nontuberculous mycobacteria].
Makarova MV; Freĭman GE
Tuberk Biolezni Legkih; 2009; (7):55-8. PubMed ID: 19697858
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
[TBL] [Abstract][Full Text] [Related]
18. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
19. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
[TBL] [Abstract][Full Text] [Related]
20. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes.
Dautzenberg B; Truffot C; Mignon A; Rozenbaum W; Katlama C; Perronne C; Parrot R; Grosset J
Tubercle; 1991 Sep; 72(3):168-75. PubMed ID: 1663282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
